Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
  • Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

BioSpace

George Church's Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

BioSpace

George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: J&J puts blockbuster blood thinner Xarelto on TrumpRx
Next: GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Related Stories

  • Pipeline

New biotech cAMPfield emerges with $180M to reshape IBD treatment

pharminent June 18, 2026
  • Pipeline

J&J adds rare disease wAIHA to Imaavy’s potential uses

pharminent June 11, 2026
  • Pipeline

Novartis gets win for another Avidity muscular dystrophy AOC

pharminent June 11, 2026

You May Have Missed

  • News

pharminent June 19, 2026
wp_daily_digest_2026-06-19
  • News

pharminent June 19, 2026
  • M&A / Deals

Biogen to acquire RayThera for up to $1bn

pharminent June 19, 2026
  • News

pharminent June 18, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.